Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis

Archives of Neurology

Volumn 68, Issue 10, 2011, Pages 1267-1271

  Farez, Mauricio F ^a   Correale, Jorge ^a  

^a FLENI   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1QB; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ADULT; ARTICLE; CASE STUDY; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; TRAVEL; YELLOW FEVER;

ADULT; BRAIN; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; MYELIN PROTEINS; PEPTIDE FRAGMENTS; RECURRENCE; RISK; TRAVEL; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 80053925481     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.131     Document Type: Article

References (20)

1. Monath TP. Yellow fever: an update. Lancet Infect Dis. 2001;1(1):11-20. (Pubitemid 33586036)
2. World Health Organization. Yellow fever vaccine: WHO position paper. Wkly Epidemiol Rec. 2003;78(40):349-359.
3. Buljevac D, Flach HZ, Hop WCJ, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002;125(pt 5):952-960. (Pubitemid 34464607)
4. Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology. 2006;67(4):652-659. (Pubitemid 44273613)
5. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet. 1995;345(8949):567-569.
6. Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S; Vaccines in Multiple Sclerosis Study Group. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med. 2001;344(5):319-326. (Pubitemid 32107639)
7. Monath TP, Barrett AD. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res. 2003;60:343-395. (Pubitemid 137639379)
8. Monath TP, Levenbook I, Soike K, et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol. 2000;74(4):1742-1751. (Pubitemid 30434031)
9. Correale J, Rush C, Amengual A, Goicochea MT. Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta. J Neuroimmunol. 2005;162(1-2):173-183.
10. Whitaker H. The self controlled case series method. BMJ. 2008;337:a1069.
11. Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine. 2004;22(15-16):2064-2070. (Pubitemid 38581081)
12. Hocine MN, Farrington CP, Touzé E, et al. Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method. Vaccine. 2007;25(31):5938-5943. (Pubitemid 47043220)
13. Staples JE, Gershman M, Fischer M; Centers for Disease Control and Prevention (CDC). Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-7):1-27.
14. Wilson ME, Chen LH, Barnett ED. Yellow fever immunizations: indications and risks. Curr Infect Dis Rep. 2004;6(1):34-42. (Pubitemid 39345316)
15. Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun. 2001;16(3):309-318. (Pubitemid 32566120)
16. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity: friends or foes? Trends Immunol. 2009;30(8):409-414.
17. Barrett ADT, Teuwen DE. Yellow fever vaccine: how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol. 2009;21(3):308-313.
18. Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009;10(1):116-125.
19. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol. 2009;9(10):741-747.
20. Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol. 2009;5(11):648-652.